Table 2. Overview of estimates for slopes across groups with different genetic risks.

Study population		n/N	n-1 (95%CI)	R-squared*
Total study population		1,124/9,362	12.82 (9.01-16.62)	0.925
APOE ・4	Carrier	481/2,624	10.56 (5.96-15.17)	0.849
	Homozygote	70/213	8.92 (5.74-12.11)	0.923
	Heterozygote	411/2,411	14.93 (8.11-21.75)	0.878
	Non-carrier	643/6,738	15.02 (11.28-18.76)	0.946
Weighted genetic risk score tertile	First	296/3,146	15.04 (9.41-20.68)	0.885
	Second	376/3,120	12.8 (9.94-15.65)	0.956
	Third	452/3,096	11.72 (7.37-16.08)	0.886
Weighted genetic risk score first tertile	APOE ・4 carrier	124/843	8.47 (1.91-15.04)	0.886
	APOE ・4 non-carrier	172/2,303	15.3 (11.77-18.82)	0.954
Weighted genetic risk score second tertile	APOE ・4 carrier	161/930	10.31 (6.83-13.79)	0.905
	APOE ・4 non-carrier	215/2,190	15.54 (12.02-19.05)	0.955
Weighted genetic risk score third tertile	APOE ・4 carrier	196/851	8.93 (3.51-14.36)	0.738
	APOE ・4 non-carrier	256/2,245	14.39 (9.81-18.97)	0.915

Abbreviations: APOE, apolipoprotein E; n, number of incident Alzheimer’s disease events; N, total number of participants; n-1, estimate for slope (i.e. number of steps minus 1).

*Obtained from linear regression model log(Alzheimer’s disease incidence_i) = β₀ + β₁*log(age_i)